Editorial
Pharmacogenetics and the treatment of cardiovascular disease
| The first 150 words of the full text of this article appear below. |
Patients with cardiovascular disease, like other patient groups, vary in their response to drugs. This is true both in terms of the response of their disease to treatment and their ability to tolerate medication. Several factors contribute to this variability, including differences in body mass, co-existent renal disease, concomitant drug treatment, and the heterogeneous nature of the disease. The Human Genome Project and the general focus of clinical science on genetic determinants of disease has increased interest in the role of genetic factors in determining an individual's response to drugs. Pharmacogenetics is a growing discipline concerned with the effect of genetic variation on the response to drugs and the extent to which drug treatment can be tailored to the individual according to their genetic makeup.
Genetic polymorphismThe idea that the dose of a drug should be adjusted according to
the patient's genotype is not new. It is well recognised
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
